Fluorine-18 radiopharmaceuticals beyond [18F]FDG for use in oncology and neurosciences

Nuclear Medicine and Biology

Volumn 37, Issue 7, 2010, Pages 727-740

  Coenen, H H ^a   Elsinga, P H ^b   Iwata, R ^c   Kilbourn, M R ^d   Pillai, M R A ^f   Rajan, M G R ^e   Wagner, H N ^g   Zaknun, J J ^f  

^a FORSCHUNGSZENTRUM JÜLICH   (Germany)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^c TOHOKU UNIVERSITY   (Japan)

^d UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^e BHABHA ATOMIC RESEARCH CENTRE   (India)

^f INTERNATIONAL ATOMIC ENERGY AGENCY   (Austria)

^g JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 FLUORO 3 (2 NITRO 1 IMIDAZOLYL) 2 PROPANOL F 18; 3' FLUOROTHYMIDINE F 18; 6 FLUORODOPA F 18; AMINO ACID OXIDASE; BORON; CARBON 11; FLUORINE 18; FLUOROCHOLINE F 18; FLUORODEOXYGLUCOSE F 18; FLUOROTYROSINE F 18; PHOSPHORUS DERIVATIVE; SILICON; SODIUM FLUORIDE F 18; TRACER; UNCLASSIFIED DRUG;

BONE CANCER; BONE METASTASIS; BRAIN MAPPING; CANCER SCINTISCANNING; CHEMICAL REACTION; DEGENERATIVE DISEASE; DIAGNOSTIC VALUE; DRUG APPROVAL; DRUG BIOAVAILABILITY; DRUG HALF LIFE; DRUG ISOLATION; DRUG SAFETY; DRUG SCREENING; DRUG SYNTHESIS; ELECTROPHILIC FLUORINATION; ENZYME ACTIVITY; FLUORINATION; HUMAN; ISOTOPE LABELING; ISOTOPE TRACING; MICROFLUIDICS; MOLECULAR IMAGING; NEUROIMAGING; NEUROSCIENCE; NONHUMAN; NUCLEOPHILIC FLUORINATION; ONCOLOGY; PEPTIDE SYNTHESIS; POSITRON EMISSION TOMOGRAPHY; PROSTATE CANCER; RADIOCHEMISTRY; RADIOISOTOPE DECAY; REVIEW; SOFT TISSUE METASTASIS; TOXICITY TESTING;

ANIMALS; FLUORODEOXYGLUCOSE F18; HUMANS; NEOPLASMS; NERVOUS SYSTEM DISEASES; RADIOPHARMACEUTICALS;

EID: 77956991351     PISSN: 09698051     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nucmedbio.2010.04.185     Document Type: Review

References (105)

1. 18F-labeled 2-deoxy-2-fluoro-d-glucose as radiopharmaceutical for measuring regional myocardial glucose metabolism in vivo: tissue distribution and imaging studies in animals. J Nucl Med 1977, 18:990-996.
2. 18F]-fluoro-2-deoxy-d-glucose using aminopolyether supported nucleophilic substitution. J Nucl Med 1986, 27:235-238.
3. U.S.Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) Guidance: PET drugs-current good manufacturing practice (CGMP): December 2009 http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm070306.pdf.
4. 18F-Labelled positron emission tomographic radiopharmaceuticals in oncology: an overview of radiochemistry and mechanism of tumor localization. Sem Nucl Med 2007, 37:400-419.
5. Mercer J.R. Molecular imaging agents for clinical positron emission tomography in oncology other than fluorodeoxyglucose (FDG): applications, limitations and potential. J Pharm Pharmaceut Sci 2007, 10:180-202.
6. International Atomic Energy Agency Radioisotope products and their availability. Nuclear Technology Review 2010, 36. http://www-govatom.iaea.org/DocumentDetails.asp?Language=English&Path=f:/websites/govatom/govatomdocs/govdoc/2010/gov-2010-05/gov2010-5.doc.
7. International Atomic Energy Agency Technical Report Series 465, cyclotron produced radionuclides: principles and practice http://www-pub.iaea.org/MTCD/publications/PDF/trs465_web.pdf.
8. International Atomic Energy Agency Technical Report Series 468, cyclotron produced radionuclides: physical characteristics and production methods http://www-pub.iaea.org/MTCD/publications/PDF/trs468_web.pdf.
9. International Atomic Energy Agency Strategies for clinical implementation and quality management of PET tracers http://www-pub.iaea.org/MTCD/publications/PubDetails.asp?pubId=7983.
10. International Atomic Energy Agency Technical Report Series 471, cyclotron produced radionuclides: Guidelines for setting up a facility http://www-pub.iaea.org/MTCD/publications/PDF/trs471_web.pdf.
11. International Atomic Energy Agency. [18F]Fluorodeoxyglucose (FDG): guidance for facility, production and quality control. IAEA Radioisotopes and Radiopharmaceuticals Series 3: [in press].
12. International Atomic Energy Agency Appropriate use of FDG PET in cancer patients: IAEA Human Health Series 9 http://www-pub.iaea.org/MTCD/publications/PDF/Pub1457_web.pdf.
13. International Atomic Energy Agency Planning a clinical PET centre: IAEA Human Health Series 11 http://www-pub.iaea.org/MTCD/publications/PDF/Pub1438_web.pdf.
14. Krohn K.A., Mankoff D.A., Muzi M., Link J.M., Spence A.M. True tracers: comparing FDG with glucose and FLT with thymidine. Nucl Med Biol 2005, 32:663-671.
15. Kilbourn M.R. Fluorine-18 Labeling of Radiopharmaceuticals 1990, National Academy Press, Washington, DC, [149 pp, NAS-NS-3203].
16. Levin C.S., Hoffman E.J. Calculation of positron range and its effect on the fundamental limit of positron emission tomography system spatial resolution. Phys Med Biol 1999, 44:781-791.
17. 18F-aryl fluorides by cleavage of aryl-tin bonds. J Fluor Chem 1984, 25:329-337.
18. 2. Nucl Med Biol 1996, 23:189-199.
19. 2. Int J Appl Rad Isot 1984, 35:117-122.
20. Bergman J., Solin O. F-18 labeled fluorine gas for synthesis of tracer molecules. Nucl Med Biol 1997, 24:677-683.
21. Coenen H.H., Moerlein S.M. Regiospecific aromatic fluorodemetallation of group IVb metalloarenes using elemental fluorine or acetyl hypofluorite. J Fluor Chem 1987, 36:63-75.
22. 18F]fluorodopa. Appl Radiat Isot 1988, 39:1203-1210.
23. 18F]fluoro-l-dopa. Appl Rad Isot 1992, 43:989-996.
24. 18F]fluoride ion. Eur J Org Chem 2008, 2853-2873.
25. Berridge M.S., Apana S.M., Hersh J.M. Teflon radiolysis as the major source of carrier in fluorine-18. J Label Comp Radiopharm 2009, 52:543-548.
26. 2 reactions catalyzed by protic solvents: Facile fluorination for isotopic labeling of diagnostic molecules. J Am Chem Soc 2006, 128:16394-16397.
27. 18F]FP-CIT using a protic solvent system. Nucl Med Biol 2007, 34:345-351.
28. PET Chemistry 2007, Springer. P.A. Schubiger, L. Lehmann, M. Friebe (Eds.).
29. 18F-fluoroalkyl agents: synthesis, reactivity and application for development of PET-ligands in molecular imaging. Curr Top Med Chem 2007, 7:1817-1828.
30. 18F]fluorobenzoate and its application to the labeling of a monoclonal antibody fragment. Bioconjug Chem 1994, 5:352-356.
31. Wester H.J., Hamacher K., Stoecklin G. A comparative study of NCA fluorine-18 labelling of proteins via acylation and photochemical conjugation. Nucl Med Biol 1996, 23:365-372.
32. 18F-fluorinated aldehydes. Nucl Med Biol 2006, 33:173-183.
33. 18F]fluoropyridine-based maleimide reagent for the labeling of peptides and proteins. Bioconjug Chem 2005, 16:406-420.
34. Rostovtsev V.V., Green L.G., Folkin V.V., Sharpless B.K. A stepwise Huisgen cycloaddition process: copper(I)-catalyzed regioselective "ligation" of azides and terminal alkynes. Angew Chem Int Ed 2002, 41:2596-2599.
35. 18F]-fluoro-5-deoxyadenosine for imaging with PET. J Lab Compd Radiopharm 2003, 46:1181-1189.
36. 18F bond formation, an enzymatic tool for PET labelling. Chem Commun (Camb) 2006, 14:652-654.
37. 18F-radiochemistry: syntheses and applications. Mini-Reviews in Organic Chemistry 2007, 4:317-329.
38. Lee C.C., Sui G., Elizarov A., Shu C.J., Shin Y.S., Dooley A.N., et al. Multistep synthesis of a radiolabeled imaging probe using integrated microfluidics. Science 2005, 16:1793-1796.
39. 18O]water in an electrochemical cell. Appl Radiat Isot 1989, 40:1-6.
40. 18O-water and subsequent no carrier added nucleophilic fluorination. Appl Radiat Isot 2002, 56:519-523.
41. 18F]fluoride. J Label Compd Radiopharm 2009, 52:S8.
42. 18F]fluoride into an aprotic solvent in a disposable microfluidic cell. J Label Compd Radiopharm 2009, 52:S505.
43. 18F]FDG. Eur J Nucl Med Mol Imaging 2009, 36:653-658.
44. Special Issue on 'positron emission tomography with fluorine-18 agents other than fluorodeoxyglucose'. Sem Nucl Med 2007, 37:399-488.
45. 18F-Fluoride positron emission tomography and positron emission tomography/computed tomography. Sem Nucl Med 2007, 462-469.
46. 18F]sodium fluoride for injection, USP to address the technetium-99m isotope shortage. Appl Radiat Isot 2010, 117-119.
47. Shields A.F., Grierson J.R., Dohmen B.M., Machulla H.J., Stayanoff J.C., Lawhorn-Crews J.M., et al. Imaging proliferation in vivo with [F-18]FLT and positron emission tomography. Nature Med 1998, 4:1334-1336.
48. 18F]FLT. Nucl Med Biol 2002, 29:263-273.
49. 11C-methylmethionine as markers of increased transport and proliferation in brain tumors. J Nucl Med 2005, 46:1948-1958.
50. 18F-FDG. J Nucl Med 2005, 46:945.
51. 18F-3-fluoro-3-deoxy-l-thymidine. Clin Cancer Res 2004, 10:1685-1690.
52. 18F-fluorocyclobutane-1-carboxylic acid with PET/CT in prostate carcinoma. J Nucl Med 2007, 48:56-63.
53. 18F]fluoroethyl)-l-tyrosine for tumor imaging. J Nucl Med 1999, 40:205-212.
54. 18F]fluoroethyl)-l-tyrosine. Appl Radiat Isot 2002, 57:853-856.
55. 18F]fluoroethyl)-l-tyrosine. Eur J Nucl Med Mol Imaging 2003, 30:519-524.
56. 18F]fluoroethyl)-l-tyrosine PET combined with MRI improves the diagnostic assessment of cerebral gliomas. Brain 2005, 128:678-687.
57. 18F-fluoroethyl-l-tyrosine PET and MRI in small nonspecific incidental brain lesions. J Nucl Med 2008, 49:730-737.
58. 18F]fluoromethyl-l-tyrosine for differentiation between tumor and inflammatory tissues. Ann Nucl Med 2005, 19:589-595.
59. Hara T., Yuasa M. Automated synthesis of fluorine-18 labeled choline analogue: 2-fluoroetheyl-dimethyl-2-oxyethylammonium. J Nucl Med 1997, 38(Supplement):44P.
60. 18F-labeled choline analogs as oncologic PET tracers. J Nucl Med 2001, 42:1805-1817.
61. 18F-labeled choline as an oncologic tracer for positron emission tomography: initial findings in prostate cancer. Cancer Res 2001, 61:110-117.
62. 18F-fluoroethylcholine for cancer imaging with PET: synthesis, biochemistry, and prostate cancer imaging. J Nucl Med 2002, 43:187-199.
63. 18F]fluorocholine. Appl Radiat Isot 2002, 57(3):347-352.
64. 18F-FDOPA: a multiple-target molecule. J Nucl Med 2009, 1915-1918.
65. 18F-DOPA PET in patients with well-differentiated metastatic neuroendocrine tumours. Eur J Nucl Med Mol Imaging 2009, 36:765-770.
66. 18F-fluorodihydroxyphenylalanine in a patient with metastatic carcinoid. J Nucl Med 2005, 46:1240-1243.
67. 18F]Fluoro-L-DOPA. Appl Radiat Isot 1999, 51:389-394.
68. 18F]fluoride. Appl Radiat Isot 2009, 67:1650-1653.
69. 18F]fluoro-1-(2-nitro-1-imidazolyl)-2-propanol. A potential PET agent for detecting hypoxic but viable tissues. Int J Radiat Appl Instrum [A] 1989, 40:117-126.
70. 18F]fluoromisonidazole. Nucl Med Biol 2005, 32:553-558.
71. 18F]FAZA: reaction parameters and automation. Appl Radiat Isot 2005, 62:897-901.
72. 18F]FRP-170 by on-column hydrolysis. Appl Radiat Isot 2005, 62:705-710.
73. 18F-FRP170 as a new PET tracer for imaging hypoxia. Ann Nucl Med 2007, 21:1-7.
74. 18F]FES) in ER positive breast cancer patients. J Pharm Pharmaceut Sci 2007, 10:256s-265s.
75. Lim J.L., Zheng L., Berridge M.S., Tewson T.J. The use of 3-methoxymethyl-16 beta, 17 beta-epiestriol-O-cyclic sulfone as the precursor in the synthesis of F-18 16 alpha-fluoroestradiol. Nucl Med Biol 1996, 23:911-915.
76. 18F]FHBG): a new potential imaging agent for viral infection and gene therapy using PET. Nucl Med Biol 1998, 25:175-180.
77. Wagner H.N. Brain Imaging 2009, Springer-Verlag London Limited.
78. 18F]GBR 12909, a dopamine reuptake inhibitor. J Labelled Comp Radiopharm 2006, 28:793-799.
79. 18F]flumazenil and its evaluation in cynomolgus monkey by positron emission tomography. Nucl Med Biol 2005, 32:109-116.
80. 18F]fluoropropyl)-2,3-dimethoxybenzamide as an improved dopamine D-2 receptor tracer. Nucl Med Biol 1995, 22:283-296.
81. 18F]FP-TZTP. Appl Radiat and Isot 2009, 67:611-616.
82. 18F]F-A85380 in Parkinson's disease. Nucl Med Biol 2006, 33:305-309.
83. 18F]fluoropropynylphenyl)-1,3-dithiane oxides: potential new GABAA receptor radioligands. Nucl Med Biol 2008, 35:549-559.
84. 18F]fluoroalkyl derivatives of dihydrotetrabenazine (DTBZ) in rat and monkey. Brain Nucl Med Biol 2007, 34:233-237.
85. 18F]fluoroethoxybenzovesamicol as a new PET tracer of cholinergic neurons of the heart. Nucl Med Biol 1994, 21:189-195.
86. 18F]fluoroethyl)piperidinyl benzilate binding to the muscarinic cholinergic receptor. Nucl Med Biol 2007, 34:479-482.
87. 18F]DOPA-PET and clinical study of the rate of the progression in Parkinson's disease. Brain 1996, 119:585-591.
88. Heiss W.D., Hilker R. The sensitivity of 18-fluorodopa positron emission tomography and magnetic resonance imaging in Parkinson's disease. Eur J Neurol 2004, 11:5-12.
89. 18F]-fluoro-L-DOPA-PET investigation. Hum Brain Map 2007, 28:931-939.
90. 18F-DOPA PET in assessing striatal and extrastriatal presynaptic dopaminergic function. Neuroimage 2010, 50:524-531.
91. 18F]FP-β-CIT). J Labelled Comp Radiopharm 2006, 49:77-89.
92. 18F]fluoroalkyl derivatives of dihydrotetrabenazine (DTBZ) in rat and monkey brain. Nucl Med Biol 2007, 34:233-237.
93. 18F]-fallypride in monkeys using a PET multiple-injection protocol. J Cereb Blood Flow Metab 2004, 24:309-322.
94. Lemaire C., Cantineau R., Guillaume M., Plenevaux A., Christiaens L. Fluorine-18-altanserin: a radioligand for the study of serotonin receptors with PET: radiolabeling and in vivo biologic behavior in rats. J Nucl Med 1991, 32:2266-2272.
95. 18F]MPPF as a tool for the in vivo imaging of 5-HT1A receptors in animal and human brain. Neuropharmacol 2007, 52:695-707.
96. 18F]FCWAY, an analog of the 5-HT1A receptor antagonist, WAY-100635. Nucl Med Biol 2000, 27:493-497.
97. 18F-FCWAY and improvement by successful inhibition of radioligand defluorination with miconazole. J Nucl Med 2006, 47:345-353.
98. 18F]cyclofoxy. Epilepsy Res 1992, 13:129-139.
99. 18F-CPFPX, a novel adenosine A1 receptor ligand: in vitro autoradiography and high-resolution small animal PET. J Nucl Med 2003, 44:1682-1689.
100. Agdeppa E.D., Kepe V., Liu J., Flores-Torres S., Satyamurthy N., Petric A., et al. Binding characteristics of radiofluorinated 6-dialkylamino-2-naphthylethylidene derivatives as positron emission tomography imaging probes for beta-amyloid plaques in Alzheimer's disease. J Neurosci 2001, 21:RC189.
101. 18F-BAY94-9172, a novel PET tracer: proof of mechanism. Lancet Neurol 2008, 7:129-135.
102. Molecular Imaging and Contrast Agent Database (MICAD) [database online]. Bethesda (MD): National Library of Medicine (US). [accessed on 23rd April 2010]. http://micad.nih.gov.
103. 99mTc]TRODAT. Nucl Med Bio 2007, 34:787-789.
104. Salvadori P.A. Radiopharmaceuticals, drug development and pharmaceuticals regulations in Europe. Current Radiopharmaceuticals 2008, 1:7-11.
105. European Medicine Agency Note for guidance on non-clinical safety studies for the conduct of human clinical trials and marketing authorization for pharmaceuticals:(CPMP/ICH/286/95) http://www.ema.europa.eu/pdfs/human/ich/028695en.pdf.